US drugmaker Forest Laboratories reported a profit of $117.5 million, or $0.39 a share for its first-quarter of fiscal 2011 ended June 30, down around 55% from $262.9 million, or $0.87 a share, a year earlier. The latest quarter included $0.56 of litigation charges and product-licensing fees. Revenue increased 6% to $1.07 billion.
Analysts polled by Thomson Reuters most recently estimated earnings of $0.86 and $1.06 billion in revenue. Forest's shares dipped 0.5% to $28.18 in morning trade on the New York Stock Exchange yesterday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze